Experimental HIV test might help improve diagnosis, treatment in developing countries

NewsGuard 100/100 Score

"Scientists have come up with a test for the virus that causes AIDS that is 10 times more sensitive and a fraction of the cost of existing methods, offering the promise of better diagnosis and treatment in the developing world," Reuters reports. "The test uses nanotechnology to give a result that can be seen with the naked eye by turning a sample red or blue, according to research from scientists at Imperial College in London published in the journal Nature Nanotechnology," the news agency writes (Wickham, 10/28). "The test can be configured to a unique signature of a disease or virus -- such as a protein found on the surface of HIV," and if the marker is present, a chemical reaction causes a blue result and a red result if the marker is not present, according to BBC News. "Early testing showed the presence of markers of HIV and prostate cancer could be detected," BBC News notes, adding, "However, trials on a much larger scale will be needed before it could be used clinically" (Gallagher, 10/28).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk